MIV-711

MIV-711 is a highly selective, orally active small molecule inhibitor of cathepsin K, an enzyme that plays a key role in the breakdown of collagen in bone and cartilage. Developed by Medivir, MIV-711 is being investigated primarily as a disease-modifying osteoarthritis drug (DMOAD) to slow or reverse the progressive degeneration of joints affected by osteoarthritis. The drug has demonstrated positive effects on both bone and cartilage in clinical studies, with evidence supporting its ability to reduce joint destruction and prevent cartilage degradation. In addition to osteoarthritis, MIV-711 has received orphan drug designation for Legg-Calve-Perthes disease (LCPD), where it aims to prevent femoral head deformity by inhibiting excessive bone resorption without negatively impacting normal bone formation[1][2][4][5].